GSK says it owns seven patents that “provide the foundation” for Moderna’s messenger RNA vaccine portfolio, and is now suing the biotechnology company for infringement. At issue is the work of a team ...

Drug company Moderna says its combined flu and Covid vaccine, which targets the two diseases in a single shot, has passed a vital part of final-stage scientific checks. The phase-three trial shows ...

Moderna said it is suing Pfizer and its German partner BioNTech for patent infringement linked to the development of the first Covid-19 vaccines. The US biotech company is alleging that mRNA ...

You really want to know what makes modern art so special? At the Pinakothek der Moderne you can satisfy your artistic curiosity. What's on offer? Exhibitions, guided tours, art workshops and a ...

This time, we have GSK (GSK) "GSK" filing a lawsuit against Moderna (NASDAQ:MRNA) accusing them of patent infringement on their lipid nanoparticle (LNP) technology, which is used in mRNA therapeutics.

Moderna Therapeutics is addressing these challenges by pioneering a new class of vaccines made of mRNA, molecules that carry instructions copied from DNA for the assembly of proteins active in ...

CAMBRIDGE, MA / ACCESSWIRE / October 31, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences: Guggenheim's Inaugural Healthcare ...

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines ...

1 Day MRNA -3.06% DJIA 0.11% S&P 500 0.02% Health Care/Life Sciences -1.00% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...